Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

1 hour ago 2

Jonathan Ponciano, The Motley Fool

Sat, May 23, 2026 astatine 5:33 PM CDT 4 min read

Superstring Capital Management disclosed a caller presumption successful Vir Biotechnology (NASDAQ:VIR), acquiring 730,548 shares successful the archetypal quarter. The estimated transaction worth was $5.82 cardinal based connected quarterly mean pricing.

What happened

According to a filing with the U.S. Securities and Exchange Commission dated May 14, 2026, Superstring Capital established a caller presumption successful Vir Biotechnology with 730,548 shares purchased. The estimated transaction worth was $5.82 million, based connected the mean unadjusted closing terms for the archetypal 4th of 2026. The fund’s quarter-end presumption successful Vir Biotechnology was valued astatine $6.55 million, reflecting some trading enactment and terms appreciation.

What other to cognize

Top holdings pursuing the filing:
- NASDAQ: SMMT: $16.93 cardinal (12.1% of AUM)
- NASDAQ: IMVT: $8.88 cardinal (6.3% of AUM)
- NASDAQ: COGT: $8.67 cardinal (6.2% of AUM)
- NASDAQ: SVRA: $8.66 cardinal (6.2% of AUM)
- NASDAQ: URGN: $6.96 cardinal (5.0% of AUM)
As of Friday, Vir Biotechnology shares were priced astatine $9.19, up 99% implicit the past twelvemonth and good outperforming the S&P 500, which is alternatively up astir 28% successful the aforesaid period.

Company Overview

Metric

Value

Revenue (TTM)	$64.7 million
Net Income (TTM)	($442.7 million)
Price (as of Friday)	$9.19
One-Year Price Change	99%

Company Snapshot

Vir develops monoclonal antibodies and RNA-based therapeutics targeting infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.
The steadfast generates gross chiefly done merchandise sales, licensing agreements, and strategical collaborations with pharmaceutical and biotechnology partners.
It serves healthcare providers, authorities agencies, and planetary wellness organizations focused connected infectious illness prevention and treatment.

Vir Biotechnology, Inc. is simply a commercial-stage biotechnology institution specializing successful the improvement of innovative immunology-based therapies for superior infectious diseases. The institution leverages collaborations with starring planetary partners to beforehand its pipeline and grow marketplace reach. Vir's strategy centers connected addressing unmet aesculapian needs done technological innovation and strategical alliances successful the healthcare sector.

What this transaction means for investors

This acquisition looks similar a stake connected catalysts alternatively than existent fiscal results. Vir remains unprofitable, but Superstring appears to beryllium positioning for what could beryllium a pivotal agelong of objective and partnership-driven developments implicit the adjacent 18 months.

The institution entered the 2nd 4th with a beardown equilibrium sheet, reporting $809.3 cardinal successful cash, currency equivalents, and investments, portion besides expecting to person an further $315 cardinal from its precocious completed Astellas collaboration and related equity investment. Just arsenic important, Vir's pipeline continues to advance. Management highlighted encouraging Phase 2 information for its chronic hepatitis delta program, with 88% of evaluated patients achieving undetectable microorganism levels done Week 96. The institution besides expects Phase 3 information from its pb hepatitis delta survey successful the 4th fourth of 2026.

Meanwhile, Vir's oncology level is gaining momentum. The institution precocious closed its prostate crab concern with Astellas, dosed the archetypal diligent successful enlargement cohorts for VIR-5500, and is targeting pivotal Phase 3 trials opening successful 2027.

For semipermanent investors, the communicative remains precocious hazard and highly babelike connected objective execution. But with a important currency runway into the 2nd fractional of 2028 and respective large information readouts ahead, this looks little similar a balance-sheet endurance communicative and much similar a institution approaching a bid of perchance value-defining milestones.

Read Entire Article